Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 2505 |
| INN | Upanovimab |
| Status | Terminated |
| Drug code(s) | SCTA01 |
| Brand name | None |
| mAb sequence source | mAb humanized |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | SARS-CoV-2 (spike protein) |
| Indications of clinical studies | COVID-19 |
| Primary therapeutic area | Infectious diseases |
| Most advanced stage of development (global) | Terminated at Phase 2/3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | July 25, 2020 |
| Start of Phase 2 | |
| Start of Phase 3 | March 27, 2021 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Sinocelltech Ltd. |
| Licensee/Partner | None |
| Comments about company or candidate | Phase 1/2 study updated in January 2022 was Withdrawn (The study was withdraw due to the fast spread of Omicron variant worldwide) NCT05156645 is An Adaptive Phase I/II/III Trial to Evaluate the Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibody Combination (SCTA01C and SCTA01) for Treatment of Outpatients With COVID-19 due to start in Jan 2022 NCT04644185 Phase 2/3 in COVID-19 started in March 2021; NCT04683328 and NCT04709328 Phase 2/3 studies not yet recruiting as of last updates in Jan and March 2021, respectively. NCT04483375 is a Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of SCTA01 in Healthy Subjects; First-in-Human Study of SCTA01(Anti-COVID-19 monoclonal antibody) in Healthy Chinese Subjects. Not yet recruiting when first posted on July 23, 2020. |
| Full address of company | No. 31, Kechuang 7th Street, Beijing Economic and Technological Development Zone Asia China http://www.sinocelltech.com/ |
Recombinant humanized anti-SARS-CoV-2 monoclonal antibody. SCTA01 and SCTA01C bind to different epitopes of the spike RBD. Produced in a Chinese hamster ovary (CHO)-DG44 cell line. SCTA01, monotherapy and in combination with SCTA01C
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |